Physician profile
Ravi Gupta
NPI 1790751949
$3,840.26
in general payments reported to CMS, 2019-2025
39 companies · $732 in 2025
The $732 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $293 · 2021: $465 · 2022: $502 · 2023: $711 · 2024: $897 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $494.87 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $445.82 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $442.64 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $241.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.65 | 2019-2024 | Jardiance |
| Nevro Corp. | $185.54 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $169.81 | 2021-2023 | Xarelto |
| Teleflex LLC | $167.74 | 2023-2025 | Barrigel, Urolift |
| Amgen INC. | $152.87 | 2020-2025 | Repatha, Otezla, Tavneos |
| Merck Sharp & Dohme LLC | $144.04 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $97.41 | 2022-2025 | Gvoke Hypopen, Keveyis |
| Abbott Laboratories | $94.47 | 2021-2022 | |
| Dexcom, INC. | $83.79 | 2023-2025 | Dexcom G6 Transmitter |
| Philips North America LLC | $81.34 | 2019-2020 | |
| Mannkind Corporation | $69.94 | 2021-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.